Loading…
← CockpitCompetitor Analysis › TRAX First Tracks Biotherapeutics IncOpen in the cockpit ↗

First Tracks Biotherapeutics IncTRAXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops antibody therapies for autoimmune and inflammatory diseases such as celiac disease, with a pipeline inherited at spinoff.

Momentum leader 98
Mkt cap
$1.87B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$28.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$44.50
1D+2.1%
1W-11.9%
1M+7.9%
3M+6.2%
6M+175.3%
YTDn/a
1Yn/a
ATR %7.2%
52w lowhigh18.8% off high

What First Tracks Biotherapeutics does

Develops antibody therapies for autoimmune and inflammatory diseases such as celiac disease, with a pipeline inherited at spinoff.

Has no product revenue, so it runs on the cash it started with and on further share sales while its antibodies are tested; value comes from trial results, possibly followed by licensing the programs to larger drug makers. It is newly separate from its former parent.

Products and services

  • ANB033 (anti-CD122, celiac disease)
  • Rosnilimab (T-cell depleting antibody)
  • ANB101 (BDCA2-modulating antibody)

Customers

  • Gastroenterologists/rheumatologists (post-approval

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Autoimmune and inflammatory disease…

What could go right

  • FDA Fast Track designation for ANB033
  • Large celiac disease unmet-need market

What could go wrong

  • Clinical trial failure risk
  • Newly independent company execution risk

Moat: none (IP / patents). Inherited a differentiated antibody pipeline at spinoff, but is newly independent with no approved products.

Headquarters: San Diego, California, US · Founded: 2019

Named competitors

First Tracks Biotherapeutics at a glance

Size First Tracks Biotherapeutics (TRAX) is a United States Health Care company (Biotechnology) with a market value of $1.87B, the 1812th largest of 3,085 United States companies the cockpit tracks. Shares closed at $44.50 on 18 Nov 2026.

Performance Over six months the shares gained 175.3%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.

Short interest Short interest is 12.0% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026TRAX 266Peer median 93
Six months, rebased to 100: First Tracks Biotherapeutics against the median of its 20 peers (local-currency closes).

First Tracks Biotherapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a-$2.42M-$2.40M
EBITDAn/a-$177M-$179M
Net incomen/a-$166M-$164M
Free cash flown/a-$143M-$126M
Capital expendituren/a$87,000$358,000
Total debt$3.77M$14.1M$16.0M

Quarterly statements and history in the cockpit →

First Tracks Biotherapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%SEPNREPLBCRX300601VERACOAGMRVITRVIZBIORXRXSTOKALMRTRAX6-month return →1-month return →
Up and to the right = strong over both horizons. First Tracks Biotherapeutics is the large dot.

First Tracks Biotherapeutics competitors and peer comparison

Head to head with its named competitors (TRAX vs 4502.T vs ANAB vs AMGN)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
First Tracks Biotherapeutics TRAX$1.87B+175%n/an/an/an/a
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%3.2×3.7%
AnaptysBio ANAB$1.40B-22%+13%62%7.9×0.5%
Amgen AMGN$240B+34%+9%36%7.2×1.6%

How First Tracks Biotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

First Tracks Biotherapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureTRAXPeer medianRank in peer set
1-month return+7.9%-6.2%4th highest of 20
6-month return+175.3%-4.7%2nd highest of 19
Distance from 52-week high-18.8%-34.3%4th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%4.9×22.7%+3.4%
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%149.9×n/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%11.7×33.0%+24.8%
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%18.8×n/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%50.6×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%3.6×-12.1%+15.0%
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a

Questions

Who are First Tracks Biotherapeutics's main competitors?
Named competitors: Takeda (4502.T), AnaptysBio (ANAB), Amgen (AMGN). The cockpit's measured peer set (industry) also includes Septerna (SEPN), Replimune (REPL), BioCryst Pharmaceuticals (BCRX), Shenzhen Kangtai Biological Products (300601.SZ), Vera Therapeutics (VERA), Sinocelltech (688520.SS).
How has First Tracks Biotherapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +175.3% against -4.7% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.